keyword
MENU ▼
Read by QxMD icon Read
search

Neoadjuvant chemotherapy of lung cancer

keyword
https://www.readbyqxmd.com/read/29675791/chemotherapy-treatment-is-associated-with-altered-pd-l1-expression-in-lung-cancer-patients
#1
Lívia Rojkó, Lilla Reiniger, Vanda Téglási, Katalin Fábián, Orsolya Pipek, Attila Vágvölgyi, László Agócs, János Fillinger, Zita Kajdácsi, József Tímár, Balázs Döme, Zoltán Szállási, Judit Moldvay
OBJECTIVES: While the predictive value of programmed cell death ligand-1 (PD-L1) protein expression for immune checkpoint inhibitor therapy of lung cancer has been extensively studied, the impact of standard platinum-based chemotherapy on PD-L1 or programmed cell death-1 (PD-1) expression is unknown. The aim of this study was to determine the changes in PD-L1 expression of tumor cells (TC) and immune cells (IC), in PD-1 expression of IC, and in the amount of stromal mononuclear cell infiltration after platinum-based chemotherapy in patients with lung cancer...
April 19, 2018: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/29673125/major-pathologic-response-and-rad51-predict-survival-in-lung-cancer-patients-receiving-neoadjuvant-chemotherapy
#2
Apar Pataer, Ruping Shao, Arlene M Correa, Carmen Behrens, Jack A Roth, Ara A Vaporciyan, Ignacio I Wistuba, Stephen G Swisher
In a previous study, we determined that major pathologic response (MPR) as indicated by the percentage of residual viable tumor cells predicted overall survival (OS) in patients with non-small-cell lung cancer (NSCLC) who received neoadjuvant chemotherapy. In this study, we assessed whether two genes and five protein biomarkers could predict MPR and OS in 98 patients with NSCLC receiving neoadjuvant chemotherapy. We collected formalin-fixed, paraffin-embedded specimens of resected NSCLC tumors from 98 patients treated with neoadjuvant chemotherapy...
April 19, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29593886/immunotherapy-in-surgically-resectable-non-small-cell-lung-cancer
#3
REVIEW
Dwight Owen, Jamie E Chaft
Surgical resection is the mainstay of therapy for patients with resectable and operable early stage non-small cell lung cancer (NSCLC). Surgery alone yields an unacceptably high rate of lung cancer recurrence. The addition of chemotherapy to surgery as adjuvant or neoadjuvant treatment can improve survival rates by roughly 5% at 5 years. Recently, major advances in cancer immunotherapy have led to better outcomes for many patients with lung cancer. Monoclonal antibodies to programmed death 1 and its ligand are now approved for both first and second line treatment patients with metastatic lung cancer...
February 2018: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/29593421/forecast-of-actin-binding-proteins-as-the-oncotarget-in-osteosarcoma-a-review-of-mechanism-diagnosis-and-therapy
#4
REVIEW
Yucheng Fu, Wei Yu, Hongliu Cai, Anwei Lu
Osteosarcoma (OS) is the most common bone malignant tumor with a high rate of lung metastasis and principally emerges in children and adolescents. Although neoadjuvant chemotherapy is widely used around the world, a high rate of chemoresistance occurs and frequently generates a poor prognosis. Therefore, finding a new appropriate prognostic marker for OS is a valuable research direction, which will give patients a better chance to receive proper therapy. Actin-binding proteins (ABPs) are a group of proteins that interact with actin cytoskeleton and play a crucial role in the regulation of the cell motility and morphology in eukaryotes...
2018: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29572004/phase-ii-trial-of-preoperative-pemetrexed-plus-carboplatin-in-patients-with-stage-ib-iii-nonsquamous-non-small-cell-lung-cancer-nsclc
#5
John D Hainsworth, David M Waterhouse, Kent C Shih, Ralph V Boccia, Victor M Priego, Michael J McCleod, Fred J Kudrik, Reed Brian Mitchell, Howard A Burris, F Anthony Greco, David R Spigel
OBJECTIVES: The combination of pemetrexed and carboplatin is a standard first-line treatment for patients with advanced NSCLC. In this pilot phase II trial, we evaluated the feasibility of using pemetrexed and carboplatin as neoadjuvant therapy, prior to definitive surgical resection, for patients with localized NSCLC. PATIENTS AND METHODS: Patients with potentially resectable, previously untreated, clinical stage IB-III, nonsquamous NSCLC were eligible for this trial...
April 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29571989/neoadjuvant-treatment-followed-by-surgery-versus-definitive-chemoradiation-in-stage-iiia-n2-non-small-cell-lung-cancer-a-multi-institutional-study-by-the-oncologic-group-for-the-study-of-lung-cancer-spanish-radiation-oncology-society
#6
F Couñago, N Rodriguez de Dios, S Montemuiño, J Jové-Teixidó, M Martin, P Calvo-Crespo, M López-Mata, M P Samper-Ots, J L López-Guerra, T García-Cañibano, V Díaz-Díaz, L de Ingunza-Barón, M Murcia-Mejía, P Alcántara, J Corona, M M Puertas, M Chust, M L Couselo, E Del Cerro, J Moradiellos, S Amor, A Varela, I J Thuissard, D Sanz-Rosa, B Taboada
OBJECTIVES: The role of surgery in stage IIIA-N2 non-small cell lung cancer (NSCLC) is an actively debated in oncology. To evaluate the value of surgery in this patient population, we conducted a multi-institutional retrospective study comparing neoadjuvant chemoradiotherapy or chemotherapy plus surgery (CRTS) to definitive chemoradiotherapy (dCRT). MATERIAL AND METHODS: A total of 247 patients with potentially resectable stage T1-T3N2M0 NSCLC treated with either CRTS or dCRT between January 2005 and December 2014 at 15 hospitals in Spain were identified...
April 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29559292/implications-of-pathologic-complete-response-beyond-mediastinal-nodal-clearance-with-high-dose-neoadjuvant-chemoradiation-therapy-in-locally-advanced-non-small-cell-lung-cancer
#7
Melissa A L Vyfhuis, Whitney M Burrows, Neha Bhooshan, Mohan Suntharalingam, James M Donahue, Josephine Feliciano, Shahed Badiyan, Elizabeth M Nichols, Martin J Edelman, Shamus R Carr, Joseph Friedberg, Gavin Henry, Shelby Stewart, Ashutosh Sachdeva, Edward M Pickering, Charles B Simone, Steven J Feigenberg, Pranshu Mohindra
PURPOSE: To determine, in a retrospective analysis of a large cohort of stage III non-small cell lung cancer patients treated with curative intent at our institution, whether having a pathologic complete response (pCR) influenced overall survival (OS) or freedom from recurrence (FFR) in patients who underwent definitive (≥60 Gy) neoadjuvant doses of chemoradiation (CRT). METHODS AND MATERIALS: At our institution, 355 patients with locally advanced non-small cell lung cancer were treated with curative intent with definitive CRT (January 2000-December 2013), of whom 111 underwent mediastinal reassessment for possible surgical resection...
February 13, 2018: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/29515398/pulmonary-sarcoidosis-activation-following-neoadjuvant-pembrolizumab-plus-chemotherapy-combination-therapy-in-a-patient-with-non-small-cell-lung-cancer-a-case-report
#8
Ghina Fakhri, Reem Akel, Ziad Salem, Ayman Tawil, Arafat Tfayli
Background: Pembrolizumab is a humanized monoclonal antibody which serves to enhance the antitumor immune response by targeting programmed cell death 1 receptor. The use of pembrolizumab plus carboplatin/pemetrexed combination therapy results in improvement in overall survival and progression-free survival rates for non-small cell lung cancer (NSCLC) patients as compared to chemotherapy alone. However, numerous immune-mediated toxicities of pembrolizumab have been reported. Case Presentation: We report the case of a 74-year-old male patient diagnosed with stage IIIA programmed death-ligand 1-positive non-small cell lung adenocarcinoma treated with 4 cycles of carboplatin/pemetrexed plus pembrolizumab combination therapy followed by 2 cycles of pembrolizumab treatment...
September 2017: Case Reports in Oncology
https://www.readbyqxmd.com/read/29484562/concurrent-versus-sequential-chemoradiation-therapy-in-completely-resected-pathologic-n2-non-small-cell-lung-cancer-propensity-matched-analysis-of-the-national-cancer-data-base
#9
Amy C Moreno, Waqar Haque, Vivek Verma, Penny Fang, Steven H Lin
BACKGROUND: Following complete resection of pN2 non-small cell lung cancer (NSCLC), national guidelines recommend either sequential (sCRT) or concurrent chemoradiotherapy (cCRT). This is the largest study to date evaluating survival between both approaches. In sCRT patients, sequencing 'chemotherapy first' versus 'radiotherapy first' was also addressed. METHODS: The National Cancer Data Base (NCDB) was queried for patients with primary NSCLC undergoing surgery (without neoadjuvant radiotherapy or chemotherapy), pN2 disease with negative surgical margins, and receiving postoperative CRT...
February 26, 2018: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29483422/-multimodality-therapy-against-the-lateral-lymph-node-recurrence-of-rectal-cancer
#10
Tomohiro Tate, Yudai Fukui, Kenji Tomizawa, Yutaka Hanaoka, Shigeo Toda, Shuichiro Matoba, Hiroya Kuroyanagi
BACKGROUND: The local recurrence of rectal cancer classifies 4 types, anterior, posterior, lateral compartment and anastomotic site. This study evaluates outcome of laparoscopic lateral lymph node dissection(LLND)against the lateral lymph node recurrence. METHOD: Five patients were diagnosed as the lateral lymph node recurrence and underwent laparoscopic LLND. We diagnosed the lateral lymph node recurrence by CT, MRI and PET-CT. All cases revealed abnormal uptake on PET-CT...
February 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29454534/sarcomatoid-carcinoma-of-the-lung-the-mayo-clinic-experience-in-127-patients
#11
Kunlatida Maneenil, Zhiqiang Xue, Ming Liu, Jennifer Boland, Fengying Wu, Shawn M Stoddard, Julian Molina, Ping Yang
BACKGROUND: Pulmonary sarcomatoid carcinoma (PSC) is an unusual form of non-small-cell lung cancer (NSCLC). Because of its rarity and heterogeneity, the treatment and prognosis of PSC have not been clearly described. METHODS AND MATERIALS: We retrospectively evaluated all patients with a diagnosis of PSC from 1997 to 2015 at the Mayo Clinic (Rochester, MN). The clinical characteristics, treatment details, and outcomes were collected. The survival rates of the PSC patients were compared with those for other subtypes of NSCLC...
December 21, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29453000/neoadjuvant-chemoradiation-shows-no-survival-advantage-to-chemotherapy-alone-in-stage-iiia-patients
#12
Seth B Krantz, Brian Mitzman, Waseem Lutfi, Kristine Kuchta, Chi-Hsiung Wang, John A Howington, Ki Wan Kim
BACKGROUND: For operable patients with clinical stage IIIA non-small cell lung cancer, the optimum neoadjuvant treatment strategy remains unclear. Our aim was to compare perioperative and long-term outcomes for patients receiving neoadjuvant chemoradiotherapy (NCRT) versus neoadjuvant chemotherapy (NCT) alone. METHODS: We queried the National Cancer Database to identify all patients with N2 and either T1-T2 non-small cell lung cancer who received either NCRT or NCT followed by lobectomy between 2006 and 2012...
February 13, 2018: Annals of Thoracic Surgery
https://www.readbyqxmd.com/read/29425685/out-of-the-darkness-and-into-the-light-new-strategies-for-improving-treatments-for-locally-advanced-non-small-cell-lung-cancer
#13
Yun Zhang, Qin Lin, Ting Xu, Weiye Deng, Jinming Yu, Zhongxing Liao, Jinbo Yue
The standard treatment for locally advanced non-small cell lung cancer (LA NSCLC) includes surgery, radiotherapy, chemotherapy, or some combination of these modalities. Many clinical trials have been conducted in attempts to intensify treatment for LA NSCLC, but with little improvement. A therapeutic plateau had been reached, with no major progress in extending survival for patients with this disease. However, several recent trials of newer targeted therapies and immunotherapies may shed new light on potential therapeutic breakthroughs...
February 6, 2018: Cancer Letters
https://www.readbyqxmd.com/read/29410947/before-or-after-evolving-neoadjuvant-approaches-to-locally-advanced-non-small-cell-lung-cancer
#14
REVIEW
Jennifer Lewis, Erin A Gillaspie, Evan C Osmundson, Leora Horn
The treatment of patients with stage IIIA ( N 2) non-small cell lung cancer (NSCLC) is one of the most challenging and controversial areas of thoracic oncology. This heterogeneous group is characterized by varying tumor size and location, the potential for involvement of surrounding structures, and ipsilateral mediastinal lymph node spread. Neoadjuvant chemotherapy, administered prior to definitive local therapy, has been found to improve survival in patients with stage IIIA ( N 2) NSCLC. Concurrent chemoradiation has also been evaluated in phase III studies in efforts to improve control of locoregional disease...
2018: Frontiers in Oncology
https://www.readbyqxmd.com/read/29394804/-a-case-of-synchronous-quadruple-cancers-treated-with-neoadjuvant-chemotherapy-followed-by-surgery
#15
Keiji Muramoto, Toru Miyake, Tomoharu Shimizu, Hiromichi Sonoda, Tomoyuki Ueki, Yoshitaka Terada, Haruki Mori, Hiromitsu Maehira, Katsushi Takebayashi, Sachiko Kaida, Hiroya Iida, Tsuyoshi Yamaguchi, Masaji Tani
The patient is male in his 60's. He underwent endoscopic examination for anemia, which was found during screening of high PSA value. Endoscopic examination revealed a gastric cancer and 3 colorectal cancers. Histological results from biopsy was HER2 positive poorly differentiated adenocarcinoma in gastric tumor and moderately differentiated adenocarcinoma in colorectal tumor. Chest CT showed a pulmonary nodule in the middle right lung. Histological diagnosis was TTF-1 positive adenocarcinoma, meaning primary lung cancer...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29362322/-a-case-of-resected-superior-sulcus-tumor-with-pathological-complete-response-after-trimodality-therapy
#16
Masaya Nishino, Kenji Tomizawa, Syuta Ohara, Toshio Fujino, Yuichi Sesumi, Takamasa Koga, Katsuaki Sato, Yoshihisa Kobayashi, Masato Chiba, Masaki Shimoji, Toshiki Takemoto, Tetsuya Mitsudomi
The current case was 73-year-oldwoman. She was referredto our hospital for an abnormal shadow of chest X-ray in the upper right lung field. Chest CT showed 3.5 cm of tumor located at the apex of right lobe with invasion of the chest wall. The tumor was diagnosed as squamous cell carcinoma using CT guided needle biopsy(superior sulcus tumor, clinical T3N0M0, Stage II B). The neoadjuvant therapy, 4 courses of chemotherapy(CBDCA plus PTX)andconcurrent radiotherapy(45 Gy/25 Fr)was performed. Chest CT revealed that tumor size was decreased to 2...
January 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29357969/-surgical-procedures-and-perioperative-management-for-non-small-cell-lung-cancer-complicated-with-left-atrial-tumor-thrombus
#17
Tong Bao, Fei Xiao, Deruo Liu, Yongqing Guo, Chaoyang Liang
BACKGROUND: Non-small cell lung cancer with left atrial tumor thrombus accounts for a small proportion of local advanced lung cancer. Whether surgery could bring benefits, as well as surgical options are still controversial, and have always been hot spots in surgical research. We report a single center experience of surgical treatment to non-small cell lung cancer with left atrial tumor thrombus, aim to figure out more reasonable treatment strategy. METHODS: From August 2006 to July 2017, a total of 11 cases of non-small cell lung cancer with left atrial tumor thrombus underwent surgery in Thoracic Surgery Department of China-Japan Friendship Hospital...
January 20, 2018: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://www.readbyqxmd.com/read/29338734/comparing-the-benefits-of-chemoradiotherapy-and-chemotherapy-for-resectable-stage-iii-a-n2-non-small-cell-lung-cancer-a-meta-analysis
#18
REVIEW
Yuqiao Chen, Xiong Peng, Yuan Zhou, Kun Xia, Wei Zhuang
BACKGROUND: Induction chemotherapy has been shown to improve survival of patients with stage III A/N2 (T1-3, N2, M0) non-small cell lung cancer (NSCLC), followed by resection, but the benefits of neoadjuvant radiotherapy still remain controversial. METHODS: PubMed, Embase, and Cochrane library databases were searched for relevant randomized controlled trials (RCTs) comparing the outcomes of induction chemoradiotherapy over induction chemotherapy, in patients with resectable stage IIIA/N2 NSCLC...
January 16, 2018: World Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29314062/postneoadjuvant-adjuvant-chemotherapy-in-resected-n1-non-small-cell-lung-cancer-with-residual-nodal-disease
#19
James W Smithy, Joshua E Rosen, Sarah J Gao, Anthony W Kim
BACKGROUND AND OBJECTIVES: Nodal positivity following neoadjuvant chemotherapy in locally advanced non-small cell lung cancer (NSCLC) is considered a poor prognostic sign, but little data are available on the efficacy of adjuvant chemotherapy in these cases. This analysis sought to determine whether adjuvant chemotherapy was associated with increased survival in NSCLC patients with residual N1 disease at resection. METHODS: Patients from the National Cancer Database (NCDB) with cN1T1-2M0 NSCLC treated with neoadjuvant chemotherapy and definitive resection between 2006 and 2012 were identified...
December 2017: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29279354/germinal-centers-determine-the-prognostic-relevance-of-tertiary-lymphoid-structures-and-are-impaired-by-corticosteroids-in-lung-squamous-cell-carcinoma
#20
Karina Silina, Alex Soltermann, Farkhondeh Movahedian Attar, Ruben Casanova, Zina M Uckeley, Helen Thut, Muriel Wandres, Sergejs Isajevs, Phil F Cheng, Alessandra Curioni Fontecedro, Periklis Foukas, Mitchell P Levesque, Holger Moch, Aija Linē, Maries van den Broek
In solid tumors, the presence of lymph node-like structures called tertiary lymphoid structures (TLS) is associated with improved patient survival. However, little is known about how TLS form in cancer, how their function affects survival, and whether they are affected by cancer therapy. In this study, we used multi-spectral microscopy, quantitative pathology and gene expression profiling to analyze TLS formation in human lung squamous cell carcinoma (LSCC) and in an experimental model of lung TLS induction...
December 26, 2017: Cancer Research
keyword
keyword
52838
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"